# Fuling Yunhua Granules and Dihuang Baoyuan Granules in Adults With Type 2 Diabetes and Inadequate Glycemic Control on Metformin Therapy

Study · id `cardio:ct-nct07929350` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07929350](<https://clinicaltrials.gov/study/NCT07929350>), retrieved 18 November 2026. No person wrote or checked this page.

Also called: NCT07929350

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 150 participants.

## Technical summary

Registry record NCT07929350. Randomized; quadruple masking; primary purpose treatment. Start 2026-11-20 (anticipated); primary completion 2028-01-15 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 150 participants (planned count; ClinicalTrials.gov record NCT07929350, source copy `cardio:ctgov-nct07929350-2026-11-10`, retrieved 2026-11-18)
- Planned start: 2026-11-20 (anticipated) (ClinicalTrials.gov record NCT07929350, source copy `cardio:ctgov-nct07929350-2026-11-10`, retrieved 2026-11-18)
- Primary completion: 2028-01-15 (anticipated) (ClinicalTrials.gov record NCT07929350, source copy `cardio:ctgov-nct07929350-2026-11-10`, retrieved 2026-11-18)
- Completion: 2028-03-15 (anticipated) (ClinicalTrials.gov record NCT07929350, source copy `cardio:ctgov-nct07929350-2026-11-10`, retrieved 2026-11-18)
- Countries: China (ClinicalTrials.gov record NCT07929350, source copy `cardio:ctgov-nct07929350-2026-11-10`, retrieved 2026-11-18)
- Care setting: Not reported
- Registry status: "NOT\_YET\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07929350-2026-11-10`, retrieved 2026-11-18)

## The registry's words

- Brief title: Fuling Yunhua Granules and Dihuang Baoyuan Granules in Adults With Type 2 Diabetes and Inadequate Glycemic Control on Metformin Therapy
- Condition: Diabetes Mellitus, Type 2
- Intervention (Drug): Fuling Yunhua Granules
- Intervention (Drug): Dihuang Baoyuan Granules
- Intervention (Drug): Fuling Yunhua Granules Matched Placebo
- Intervention (Drug): Dihuang Baoyuan Granules Matched Placebo
- Intervention (Drug): Metformin
- Intervention (Drug): Metformin Matched Placebo
- Lead sponsor: Beijing Supreme Life Pharmaceutical Technology Co., Ltd.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)

## Provenance

Content hash: b3082974aa1421877e454bdb68c1790d08b8178f97db83aecf151987d0380447
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
